POLARITYTE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Information

On January 18, 2022, PolarityTE, Inc., issued a press release titled "PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication." A copy of the press release is included with the filing as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.




Exhibit No.   Description

99.1            Press release dated January 18, 2022, titled "PolarityTE Announces
              U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to
              Support Chronic Cutaneous Ulcer Indication."
104           Cover Page Interactive Data File, formatted in Inline XBRL

© Edgar Online, source Glimpses